Improvement of Active Rheumatoid Arthritis After Etanercept Injection: A Single-center Experience

Journal of the Chinese Medical Association

Volumn 72, Issue 11, 2009, Pages 581-587

  Su, Kuei Ying ^a,b   Lee, Hui Ting ^c   Chou, Chung Tei ^c   Tsai, Shih Tzu ^a   Chen, Wei Sheng ^c   Tsai, Chang Youh ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

biological therapies; etanercept; rheumatoid arthritis; tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CELLULITIS; COMBINATION CHEMOTHERAPY; COMMON COLD; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY ABSCESS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRURITUS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74249115785     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70433-2     Document Type: Article

References (32)

1. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
2. Dayer J.M. Interleukin 1 or tumor necrosis factor-α: Which is the real target in rheumatoid arthritis?. J Rheumatol 29 Suppl (2002) 10-15
3. Hata H., Sakaguchi N., Yoshitomi H., Iwakura Y., Sekikawa K., Azuma Y., Kanai C., et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114 (2004) 582-588
4. Arend W.P., and Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38 (1995) 151-160
5. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
6. Weisman M.H., Paulus H.E., Burch F.X., Kivitz A.J., Fierer J., Dunn M., Kerr D.R., et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 46 (2007) 1122-1125
7. Keystone E.C., Schiff M.H., Kremer J.M., Kafka S., Lovy M., DeVries T., and Burge D.J. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50 (2004) 353-363
8. Nixon R., Bansback N., and Brennan A. The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 46 (2007) 1140-1147
9. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., Richert J.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869
10. Kwon H.J., Coté T.R., Cuffe M.S., Kramer J.M., and Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138 (2003) 807-811
11. Gómez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D., and BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predis-pose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
12. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
13. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified Disease Activity Scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
14. van Gestel A.M., Haagsma C.J., and van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41 (1998) 1845-1850
15. Chen H.A., Lin K.C., Chen C.H., Liao H.T., Wang H.P., Chang H.N., Tsai C.Y., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factors in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 35-39
16. van der Helm-van Mil A.H., Breedveld F.C., and Huizinga T.W. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 8 (2006) 216-222
17. O'Gradaigh D., Ireland D., Bord S., and Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63 (2004) 354-359
18. Saxne T., Palladino Jr. M.A., Heinegård D., Talal N., and Wollheim F.A. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31 (1988) 1041-1045
19. Nash P.T., and Florin T.H.J. Tumour necrosis factor inhibitors. Med J Aust 183 (2005) 205-208
20. Wooley P.H., Dutcher J., Widmer M.B., and Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151 (1993) 6602-6607
21. Fisher Jr. C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., Abraham E., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334 (1996) 1697-1702
22. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
23. Allendoerfer R., and Deepe Jr. G.S. Blockade of endogenous TNF-α exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 160 (1998) 6072-6082
24. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-571
25. Garcia I., Miyazaki Y., Marchal G., Lesslauer W., and Vassalli P. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-γ in the differentiation of protective granulomas. Eur J Immunol 27 (1997) 3182-3190
26. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., and Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731-740
27. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Genovese M.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
28. Seong S.S., Choi C.B., Woo J.H., Bae K.W., Joung C.L., Uhm W.S., Kim T.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34 (2007) 706-711
29. Dimakou K., Papaioannides D., Latsi P., Katsimboula S., Korantzopoulos P., and Orphanidou D. Disseminated tuberculosis complicating anti-TNF-α treatment. Int J Clin Pract 58 (2004) 1052-1055
30. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., Dougados M., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 (2006) 2136-2146
31. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
32. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450